These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38947326)

  • 1. Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin's lymphoma.
    Frame DG; Geer M; Kasha S; Markstrom D; Scappaticci G; Feeney T; Hayduk A; Mansoor HM; Oberfeld A; D'Antonio H; Anand S; Choi SW; Maciejewski J; Pawarode A; Riwes MM; Tewari M; Magenau J; Ghosh M
    Front Immunol; 2024; 15():1403145. PubMed ID: 38947326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
    Turtle CJ; Hanafi LA; Berger C; Hudecek M; Pender B; Robinson E; Hawkins R; Chaney C; Cherian S; Chen X; Soma L; Wood B; Li D; Heimfeld S; Riddell SR; Maloney DG
    Sci Transl Med; 2016 Sep; 8(355):355ra116. PubMed ID: 27605551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
    Locke FL; Ghobadi A; Jacobson CA; Miklos DB; Lekakis LJ; Oluwole OO; Lin Y; Braunschweig I; Hill BT; Timmerman JM; Deol A; Reagan PM; Stiff P; Flinn IW; Farooq U; Goy A; McSweeney PA; Munoz J; Siddiqi T; Chavez JC; Herrera AF; Bartlett NL; Wiezorek JS; Navale L; Xue A; Jiang Y; Bot A; Rossi JM; Kim JJ; Go WY; Neelapu SS
    Lancet Oncol; 2019 Jan; 20(1):31-42. PubMed ID: 30518502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.
    Hirayama AV; Gauthier J; Hay KA; Voutsinas JM; Wu Q; Gooley T; Li D; Cherian S; Chen X; Pender BS; Hawkins RM; Vakil A; Steinmetz RN; Acharya UH; Cassaday RD; Chapuis AG; Dhawale TM; Hendrie PC; Kiem HP; Lynch RC; Ramos J; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2019 Apr; 133(17):1876-1887. PubMed ID: 30782611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.
    Ghilardi G; Chong EA; Svoboda J; Wohlfarth P; Nasta SD; Williamson S; Landsburg JD; Gerson JN; Barta SK; Pajarillo R; Myers J; Chen AI; Schachter L; Yelton R; Ballard HJ; Hodges Dwinal A; Gier S; Victoriano D; Weber E; Napier E; Garfall A; Porter DL; Jäger U; Maziarz RT; Ruella M; Schuster SJ
    Ann Oncol; 2022 Sep; 33(9):916-928. PubMed ID: 35690221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
    Lutfi F; Holtzman NG; Kansagra AJ; Mustafa Ali M; Bukhari A; Yan J; Samanta S; Gottlieb D; Kim DW; Matsumoto LR; Gahres N; Ruehle K; Lee ST; Law JY; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; Molitoris J; Mohindra P; Rapoport AP; Dahiya S
    Br J Haematol; 2021 Nov; 195(3):405-412. PubMed ID: 34500492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies.
    Gauthier J; Bezerra ED; Hirayama AV; Fiorenza S; Sheih A; Chou CK; Kimble EL; Pender BS; Hawkins RM; Vakil A; Phi TD; Steinmetz RN; Jamieson AW; Bar M; Cassaday RD; Chapuis AG; Cowan AJ; Green DJ; Kiem HP; Milano F; Shadman M; Till BG; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2021 Jan; 137(3):323-335. PubMed ID: 32967009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.
    Chong EA; Chong ER; Therwhanger D; Nasta SD; Landsburg DJ; Barta SK; Svoboda J; Gerson JN; Ghilardi G; Paruzzo L; Fraietta JA; Weber E; Stefano N; Porter DL; Frey NV; Garfall AL; Ruella M; Schuster SJ
    Transplant Cell Ther; 2024 Jul; 30(7):726.e1-726.e8. PubMed ID: 38494076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustine is a safe and effective lymphodepletion agent for axicabtagene ciloleucel in patients with refractory or relapsed large B-cell lymphoma.
    Bharadwaj S; Lau E; Hamilton MP; Goyal A; Srinagesh H; Jensen A; Lee D; Mallampet J; Elkordy S; Syal S; Patil S; Latchford T; Sahaf B; Arai S; Johnston LJ; Lowsky R; Negrin R; Rezvani AR; Shizuru J; Meyer EH; Shiraz P; Mikkilineni L; Weng WK; Smith M; Sidana S; Muffly L; Maecker HT; Frank MJ; Mackall C; Miklos D; Dahiya S
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 38955420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.
    Ong SY; Pak S; Mei M; Wang Y; Popplewell L; Baird JH; Herrera AF; Shouse G; Nikolaenko L; Zain J; Godfrey J; Htut M; Aribi A; Spielberger R; Mansour J; Forman SJ; Palmer J; Budde LE
    Am J Hematol; 2023 Nov; 98(11):1751-1761. PubMed ID: 37668287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.
    Kochenderfer JN; Dudley ME; Kassim SH; Somerville RP; Carpenter RO; Stetler-Stevenson M; Yang JC; Phan GQ; Hughes MS; Sherry RM; Raffeld M; Feldman S; Lu L; Li YF; Ngo LT; Goy A; Feldman T; Spaner DE; Wang ML; Chen CC; Kranick SM; Nath A; Nathan DA; Morton KE; Toomey MA; Rosenberg SA
    J Clin Oncol; 2015 Feb; 33(6):540-9. PubMed ID: 25154820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
    Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
    BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors.
    Miller A; Daum R; Wang T; Wu M; Tat C; Pfeiffer T; Navai S; Heczey A; Hegde M; Ahmed N; Whittle SB; Hill L; Martinez C; Krance R; Ramos CA; Rouce RH; Lulla P; Heslop HE; Omer B; Shekar M
    Cytotherapy; 2024 Sep; 26(9):1026-1032. PubMed ID: 38819365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.
    Ahmed N; Wesson W; Lutfi F; Porter DL; Bachanova V; Nastoupil LJ; Perales MA; Maziarz RT; Brower J; Shah GL; Chen AI; Oluwole OO; Schuster SJ; Bishop MR; McGuirk JP; Riedell PA
    Blood Adv; 2024 Oct; 8(20):5346-5354. PubMed ID: 39042880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report.
    Liang Z; Zhang H; Shao M; Cui Q; Wu Z; Xiao L; Huang H; Hu Y
    Medicine (Baltimore); 2020 Oct; 99(43):e22510. PubMed ID: 33120740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
    Gagelmann N; Bishop M; Ayuk F; Bethge W; Glass B; Sureda A; Pasquini MC; Kröger N
    Transplant Cell Ther; 2024 Jun; 30(6):584.e1-584.e13. PubMed ID: 38281590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
    Jacobson CA; Chavez JC; Sehgal AR; William BM; Munoz J; Salles G; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; Yakoub-Agha I; Oluwole OO; Fung HCH; Rosenblatt J; Rossi JM; Goyal L; Plaks V; Yang Y; Vezan R; Avanzi MP; Neelapu SS
    Lancet Oncol; 2022 Jan; 23(1):91-103. PubMed ID: 34895487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
    Front Immunol; 2021; 12():745320. PubMed ID: 34712233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.
    Locke FL; Neelapu SS; Bartlett NL; Siddiqi T; Chavez JC; Hosing CM; Ghobadi A; Budde LE; Bot A; Rossi JM; Jiang Y; Xue AX; Elias M; Aycock J; Wiezorek J; Go WY
    Mol Ther; 2017 Jan; 25(1):285-295. PubMed ID: 28129122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.